These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Has combined modality therapy improved the outlook in carcinoma of the esophagus?
    Author: Philip PA, Ajani JA.
    Journal: Oncology (Williston Park); 1994 Sep; 8(9):37-42; discussion 44-5, 50-2, 61. PubMed ID: 7527642.
    Abstract:
    Carcinoma of the esophagus or the gastroesophageal junction is uncommon, accounting for approximately 1% of all malignancies in the United States. Approximately 11,000 new cases and 10,400 deaths are estimated in 1994. The diagnosis is often made late in Western countries, thus T3, T4, and N-positive lesions are encountered frequently. Nearly 50% of patients have advanced incurable disease at the time of diagnosis. Therefore, the prognosis of patients with carcinoma of the esophagus remains poor and the overall 5-year survival rates are still under 10%. The answer to the question in the title is yes, at least for some patients, on a short-term basis.
    [Abstract] [Full Text] [Related] [New Search]